The COVID-19 pandemic severely disrupted cardiovascular care during the spring of 2020 in Europe . Our study analyzed the clinical profile, COVID-19 impact, and 30-day prognosis of invasively managed patients with acute coronary syndrome (ACS) compared to a historical cohort.All invasively managed ACS patients from March 1st to April 30th, 2020 were compared to a cohort from the same timeframe of 2019 (n = 316). COVID-19 confirmed cases were defined by a positive SARS-CoV-2 polymerase chain reaction (PCR) test (CoV+). The primary outcome was all-cause 30-day mortality and multivariable predictors of this outcome.A 40.4% reduction in ACS patients was noted (198 cases in 2019 to 118 in 2020), and 11% of 2020 ACS patients were CoV+ . Baseline characteristics were similar between groups . There were significantly more in-hospital patients with ACS (15.3% versus 6.1%, P = 0.007), and fewer patients were found to have a culprit lesion (58.5% versus 74.2%, P = 0.004) in 2020 compared to 2019 . Thirty-day mortality in 2020 (7 %) was not different from that in 2019 (4.2 %), P = 0.294, but it was significantly higher in CoV+ patients (23.1 %) compared to that in negative SARS-CoV-2 PCR test (CoV-) patients (5 %), P = 0.047, in the 2020 group . In the multivariate analysis, CoV+ was an independent mortality predictor (OR = 9.8 , 95% CI = 1.48-64.78), along with the left ventricular ejection fraction (LVEF) (OR = 0.91 , 95% CI = 0.86-0.97), P = 0.0006.This study found increased 30-day mortality of invasively managed CoV+ ACS patients compared to that of CoV- patients during the 2020 COVID-19 spring outbreak . In the multivariable analysis, a SARS-CoV-2 positive test was independently associated with 30-day mortality . Further investigations of the underlying physiopathological relations between COVID-19 and ACS are warranted.
Index: Myocardial infarction, Percutaneous coronary intervention, SARS-CoV-2 PCR